Page 1 | Search Results | Blood Advances | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Active infection at the time of CD34 + selected stem cell boost is associated with treatment failure and poor overall survival

Blood Adv (2024) 8 (17): 4729–4737.

https://doi.org/10.1182/bloodadvances.2023012418

Published: 2024

Includes: Supplemental data

Journal Articles

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Blood Adv (2024) 8 (4): 978–990.

https://doi.org/10.1182/bloodadvances.2023012120

Published: 2024

Includes: Supplemental data

Journal Articles

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse

Roman M. Shapiro, Haesook T. Kim, Michela Ansuinelli, Indira Guleria, Corey S. Cutler, John Koreth, Mahasweta Gooptu, Joseph H. Antin, Amar Kelkar, Jerome Ritz, Catherine J. Wu, Robert J. Soiffer, Vincent T. Ho, Sarah Nikiforow, Rizwan Romee

Blood Adv (2023) 7 (15): 4080–4088.

https://doi.org/10.1182/bloodadvances.2023009657

Published: 2023

Includes: Supplemental data

Journal Articles

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD

Katie Maurer, Vincent T. Ho, Eno Inyang, Corey Cutler, John Koreth, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, Joseph H. Antin, Catherine J. Wu, Jerome Ritz, Robert J. Soiffer, Haesook T. Kim

Blood Adv (2023) 7 (15): 3903–3915.

https://doi.org/10.1182/bloodadvances.2023009791

Published: 2023

Includes: Supplemental data

Journal Articles

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells

Katie Maurer, Haesook T. Kim, Heather M. Garrity, Deborah Liney, Corey Cutler, Joseph H. Antin, John Koreth, Jerome Ritz, Roman M. Shapiro, Rizwan Romee, Vincent T. Ho, Mahasweta Gooptu, Robert J. Soiffer, Catherine J. Wu, Sarah Nikiforow

Blood Adv (2023) 7 (11): 2431–2435.

https://doi.org/10.1182/bloodadvances.2022009231

Published: 2023

Journal Articles

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis

Mahasweta Gooptu, Haesook T. Kim, Eric Jacobsen, David C. Fisher, Ann LaCasce, Vincent T. Ho, Corey S. Cutler, John Koreth, Robert J. Soiffer, Joseph H. Antin, Nancy Berliner, Sarah Nikiforow

Blood Adv (2023) 7 (11): 2309–2316.

https://doi.org/10.1182/bloodadvances.2022007012

Published: 2023

Includes: Supplemental data

Journal Articles

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

Blood Adv (2022) 6 (7): 2183–2194.

https://doi.org/10.1182/bloodadvances.2021006255

Published: 2022

Includes: Supplemental data

Journal Articles

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant

Mary Nauffal, Haesook T. Kim, Paul G. Richardson, Robert J. Soiffer, Joseph H. Antin, Corey Cutler, Sarah Nikiforow, Mahasweta Gooptu, John Koreth, Rizwan Romee, Vincent T. Ho

Blood Adv (2022) 6 (1): 181–188.

https://doi.org/10.1182/bloodadvances.2021005410

Published: 2022

Includes: Supplemental data

Journal Articles

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Blood Adv (2021) 5 (24): 5536–5545.

https://doi.org/10.1182/bloodadvances.2021005566

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution

Katie Maurer, Haesook T. Kim, Thomas M. Kuczmarski, Heather M. Garrity, Augustine Weber, Carol G. Reynolds, Deborah Liney, Corey Cutler, Joseph H. Antin, John Koreth, Jerome Ritz, Roman M. Shapiro, Rizwan Romee, Catherine J. Wu, Robert J. Soiffer, Sarah Nikiforow, Vincent T. Ho, Mahasweta Gooptu

Blood Adv (2021) 5 (23): 5140–5149.

https://doi.org/10.1182/bloodadvances.2021005139

Published: 2021

Includes: Supplemental data

Journal Articles

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience

Katie Maurer, Anna Saucier, Haesook T. Kim, Utkarsh Acharya, Clifton C. Mo, Julie Porter, Cindy Albert, Corey Cutler, Joseph H. Antin, John Koreth, Mahasweta Gooptu, Rizwan Romee, Catherine J. Wu, Robert J. Soiffer, Sarah Nikiforow, Caron Jacobson, Vincent T. Ho

Blood Adv (2021) 5 (3): 861–871.

https://doi.org/10.1182/bloodadvances.2020003883

Published: 2021

Includes: Supplemental data

Journal Articles

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide

Benedetta Rambaldi, Haesook T. Kim, Carol Reynolds, Sharmila Chamling Rai, Yohei Arihara, Tomohiro Kubo, Leutz Buon, Mahasweta Gooptu, John Koreth, Corey Cutler, Sarah Nikiforow, Vincent T. Ho, Edwin P. Alyea, Joseph H. Antin, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Rizwan Romee

Blood Adv (2021) 5 (2): 352–364.

https://doi.org/10.1182/bloodadvances.2020003005

Published: 2021

Includes: Supplemental data

Journal Articles

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

Haesook T. Kim, Conner J. Shaughnessy, Sharmila C. Rai, Carol Reynolds, Vincent T. Ho, Corey Cutler, John Koreth, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, Philippe Armand, Edwin P. Alyea, Joseph H. Antin, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Jennifer R. Brown

Blood Adv (2020) 4 (17): 4113–4123.

https://doi.org/10.1182/bloodadvances.2020002184

Published: 2020

Includes: Supplemental data

Journal Articles

BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation

Blood Adv (2020) 4 (9): 1881–1893.

https://doi.org/10.1182/bloodadvances.2019001120

Published: 2020

Includes: Supplemental data

Journal Articles

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL

Blood Adv (2019) 3 (3): 360–369.

https://doi.org/10.1182/bloodadvances.2018027748

Published: 2019

Includes: Supplemental data

NARROW

Active infection at the time of CD34 + selected stem cell boost is associated with treatment failure and poor overall survival

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only